Surgery in the treatment of malignant pleural mesothelioma: Recruitment into trials should be the default position

Thorax

Volumn 69, Issue 2, 2014, Pages 194-197

  Datta, Avijit ^a,b   Smith, Rhiannon ^b   Fiorentino, Francesca ^c   Treasure, Tom ^d  

^a YORK TEACHING HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PEMETREXED;

ADJUVANT THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL DECISION MAKING; EXTRAPLEURAL PNEUMONECTOMY; HUMAN; LUNG RESECTION; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PHYSICIAN ATTITUDE; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURECTOMY DECORTICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; THORACOTOMY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

MESOTHELIOMA; THORACIC SURGERY;

AGED; ENGLAND; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PATIENT SELECTION; PLEURAL NEOPLASMS; PNEUMONECTOMY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84892505796     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203846     Document Type: Article

References (38)

1. Peto J, Hodgson JT, Matthews FE, et al. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345: 535-9.
2. La Vecchia C, Decarli A, Peto J, et al. An age, period and cohort analysis of pleural cancer mortality in Europe. Eur J Cancer Prev 2000;9: 179-84. (Pubitemid 30395355)
3. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92: 587-93. (Pubitemid 40395543)
4. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27: 2081-90.
5. Wang X, Yano E, Qiu H, et al. A 37-year observation of mortality in Chinese chrysotile asbestos workers. Thorax 2012;67: 106-10.
6. Hiddinga BI, van Meerbeeck JP. Surgery in mesothelioma - where do we go after Mars? J Thorac Oncol 2013;8: 525-9.
7. Cao CQ, Yan TD, Bannon PG, et al. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010;5: 1692-703.
8. Teh E, Fiorentino F, Tan C, et al. A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. J R Soc Med 2011;104: 69-80.
9. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7: 1157-68. (Pubitemid 19196542)
10. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-44. (Pubitemid 46606305)
11. Smith R, Datta AK, Ten year follow up of mesothelioma in North Yorkshire. Thorax 2012:A150-A151.
12. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012;7: 1631-9.
13. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12: 763-72.
14. Tan C, Swift S, Gilham C, et al. Survival in surgically diagnosed patients with malignant mesothelioma in current practice. Thorax 2002;57iii: 36.
15. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364: 1183-5. (Pubitemid 39296609)
16. Treasure T, Waller D, Swift S, et al. Radical surgery for mesothelioma. BMJ 2004;328: 237-8. (Pubitemid 38168126)
17. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011;12: 1093-4.
18. Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress; 11-14 September 2012, Boston. J Thorac Cardiovasc Surg 2013;145: 909-10.
19. Treasure T, Utley M, O'Byrne K. MARS a sense of perspective and an inconvenient truth. J Thorac Oncol 2013;8:e48-9.
20. Bliss JM, Coombes G, Darlison L, et al. The MARS feasibility trial: correspondence. Lancet Oncol 2011;12: 1094-5.
21. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995;311: 1621-5. (Pubitemid 26002712)
22. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84: 1685-92.
23. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135: 620-6.
24. Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009;138: 405-11.
25. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2: 957-65. (Pubitemid 47511601)
26. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7: 737-43.
27. Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: A harmful procedure. Lung Cancer 2012;77: 151-5.
28. Steele J. Randomised trial of extended pleurectomy and decortication (EPD) with pemetrexed and platinum chemotherapy versus pemetrexed and platinum alone in patients with malignant pleural mesothelioma ('MARS-2'). Proc IMIG 2012; 12-14 September 2012, Boston. 2012:P3.22. http://www.imig2012.org/ documents/iMig2012-AbstractBook-vF-Sept10-REV.pdf
29. NCCN guidelines for patients: malignant pleural mesothelioma: national cancer collaborative network. http://www.nccn.org/patients/patient-guidelines/ mpm/files/assets/basic-html/page22.html
30. Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med 2012;156: 525-31.
31. Treasure T, Utley M. Statistics for the rest of us: ten traps for the unwary in surgical series: a case study in mesothelioma reports. J Thorac Cardiovasc Surg 2007;133: 1414-18. (Pubitemid 46805160)
32. Utley M, Fiorentino F, Treasure T. Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma. Eur J Cardiothorac Surg 2010;38: 241-4.
33. Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in Western Australia. J Thorac Oncol 2009;4: 1010-16.
34. Treasure T, Internullo E, Fiorentino F, et al. A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS). Interact Cardiovasc Thorac Surg 2011;12: 341-6.
35. Rena O, Casadio C. Lack of evidence in malignant pleural mesothelioma surgery. Interact Cardiovasc Thorac Surg 2011;12: 347-8.
36. Ploenes T, Osei-Agyemang T, Krohn A, et al. Changes in lung function after surgery for mesothelioma. Asian Cardiovasc Thorac Ann 2013;21: 48-55.
37. Russell RCG, Treasure T. Counting the cost of cancer surgery for advanced and metastatic disease. Br J Surg 2012;99: 449-50.
38. Treasure T, Morton D. GRIST growing recruitment in interventional and surgical trials. J R Soc Med 2012;105: 140-1.